Target Name: USP34
NCBI ID: G9736
Review Report on USP34 Target / Biomarker Content of Review Report on USP34 Target / Biomarker
USP34
Other Name(s): ubiquitin specific protease 34 | ubiquitin-specific-processing protease 34 | ubiquitin thioesterase 34 | ubiquitin specific peptidase 34 | Deubiquitinating enzyme 34 | Ubiquitin specific peptidase 34 | Ubiquitin thiolesterase 34 | ubiquitin thiolesterase 34 | KIAA0729 | deubiquitinating enzyme 34 | Ubiquitin thioesterase 34 | Ubiquitin specific protease 34 | KIAA0570 | Ubiquitin-specific-processing protease 34 | Ubiquitin carboxyl-terminal hydrolase 34 | UBP34_HUMAN

USP34: A Potential Drug Target and Biomarker

Ubiquitin specific protease 34 (USP34) is a protein that plays a critical role in the ubiquitin system, a protein degradation pathway that is essential for cell signaling and tissue repair. Mutations in the USP34 gene have been linked to a range of diseases, including cancer , neurodegenerative diseases, and autoimmune disorders. As a result, USP34 has emerged as a promising drug target and biomarker for a variety of diseases.

The ubiquitin system is a complex protein degradation pathway that involves a series of enzymes that remove a single amino acid residue from each Ubiquin protein. The ubiquitin system is critical for the regulation of a wide range of cellular processes, including cell signaling, DNA replication, and immune responses. USP34 is one of the key enzymes in the ubiquitin system that removes a ubiquitin protein from its substrate.

Mutations in the USP34 gene have been linked to a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that USP34 mutations are associated with an increased risk of colorectal cancer and breast cancer. Additionally, USP34 mutations have also been linked to neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

As a result, USP34 has emerged as a promising drug target for a variety of diseases. One approach to targeting USP34 is to use small molecules, such as drugs that can inhibit the activity of USP34. These drugs could be used to treat a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach to targeting USP34 is to use antibodies that recognize and label USP34 and its clients. Additionally, these antibodies could be used to diagnose and monitor a variety of diseases, including cancer and neurodegenerative disorders. Additionally, these antibodies could be used to target USP34 and its clients. clients with drugs that are designed to inhibit their activity.

Another potential approach to targeting USP34 is to use RNA-based therapies. RNA of the USP34 gene can inhibit its removal of the protein by inhibiting its activity. These drugs can be used to treat a variety of diseases, including cancer, neurodegenerative diseases and autoimmune diseases.

In conclusion, USP34 is a protein that plays a critical role in the ubiquitin system and has been linked to a range of diseases. As a result, USP34 has emerged as a promising drug target and biomarker for a variety of diseases. Further research is needed to understand the full potential of USP34 as a drug and to develop effective treatments for the treatment of these diseases.

Protein Name: Ubiquitin Specific Peptidase 34

Functions: Ubiquitin hydrolase that can remove conjugated ubiquitin from AXIN1 and AXIN2, thereby acting as a regulator of Wnt signaling pathway. Acts as an activator of the Wnt signaling pathway downstream of the beta-catenin destruction complex by deubiquitinating and stabilizing AXIN1 and AXIN2, leading to promote nuclear accumulation of AXIN1 and AXIN2 and positively regulate beta-catenin (CTNBB1)-mediated transcription. Recognizes and hydrolyzes the peptide bond at the C-terminal Gly of ubiquitin. Involved in the processing of poly-ubiquitin precursors as well as that of ubiquitinated proteins

The "USP34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1 | VAT1L | VAV1 | VAV2 | VAV3 | VAV3-AS1 | VAX1 | VAX2 | VBP1 | VCAM1 | VCAN | VCL | VCP | VCPIP1 | VCPKMT | VCX | VCX2 | VCX3A | VCX3B | VCY